{"title":"经济学如何解释阿尔茨海默病?","authors":"A. Chandra, Courtney C. Coile, Corina D Mommaerts","doi":"10.1257/jel.20211660","DOIUrl":null,"url":null,"abstract":"Alzheimer’s disease (AD) affects one in ten people aged 65 or older and is the most expensive disease in the United States. We describe the central economic questions raised by AD. Although there is overlap with the economics of aging and health, the defining feature of the “economics of Alzheimer’s disease” is an emphasis on choice by cognitively impaired patients that affects health and financial well-being, and situations in which dynamic contracts between patients and caregivers are useful but difficult to enforce. A focus on innovation in AD prevention, treatment, and care is also critical given the enormous social cost of AD and present lack of understanding of its causes, which raises questions of optimal resource allocation and alignment of private and social incentives. The enormous scope for economists to contribute to our understanding of AD-related issues including drug development, efficient care delivery, dynamic contracting, long-term care risk, financial decision-making, and the design of public programs for AD suggests a rich research program for many areas of economics. (JEL G22, G50, I10, I38, J14, L65, O31)","PeriodicalId":48416,"journal":{"name":"Journal of Economic Literature","volume":" ","pages":""},"PeriodicalIF":11.5000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":"{\"title\":\"What Can Economics Say about Alzheimer’s Disease?\",\"authors\":\"A. Chandra, Courtney C. Coile, Corina D Mommaerts\",\"doi\":\"10.1257/jel.20211660\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Alzheimer’s disease (AD) affects one in ten people aged 65 or older and is the most expensive disease in the United States. We describe the central economic questions raised by AD. Although there is overlap with the economics of aging and health, the defining feature of the “economics of Alzheimer’s disease” is an emphasis on choice by cognitively impaired patients that affects health and financial well-being, and situations in which dynamic contracts between patients and caregivers are useful but difficult to enforce. A focus on innovation in AD prevention, treatment, and care is also critical given the enormous social cost of AD and present lack of understanding of its causes, which raises questions of optimal resource allocation and alignment of private and social incentives. The enormous scope for economists to contribute to our understanding of AD-related issues including drug development, efficient care delivery, dynamic contracting, long-term care risk, financial decision-making, and the design of public programs for AD suggests a rich research program for many areas of economics. (JEL G22, G50, I10, I38, J14, L65, O31)\",\"PeriodicalId\":48416,\"journal\":{\"name\":\"Journal of Economic Literature\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":11.5000,\"publicationDate\":\"2023-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Economic Literature\",\"FirstCategoryId\":\"96\",\"ListUrlMain\":\"https://doi.org/10.1257/jel.20211660\",\"RegionNum\":1,\"RegionCategory\":\"经济学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ECONOMICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Economic Literature","FirstCategoryId":"96","ListUrlMain":"https://doi.org/10.1257/jel.20211660","RegionNum":1,"RegionCategory":"经济学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ECONOMICS","Score":null,"Total":0}
Alzheimer’s disease (AD) affects one in ten people aged 65 or older and is the most expensive disease in the United States. We describe the central economic questions raised by AD. Although there is overlap with the economics of aging and health, the defining feature of the “economics of Alzheimer’s disease” is an emphasis on choice by cognitively impaired patients that affects health and financial well-being, and situations in which dynamic contracts between patients and caregivers are useful but difficult to enforce. A focus on innovation in AD prevention, treatment, and care is also critical given the enormous social cost of AD and present lack of understanding of its causes, which raises questions of optimal resource allocation and alignment of private and social incentives. The enormous scope for economists to contribute to our understanding of AD-related issues including drug development, efficient care delivery, dynamic contracting, long-term care risk, financial decision-making, and the design of public programs for AD suggests a rich research program for many areas of economics. (JEL G22, G50, I10, I38, J14, L65, O31)
期刊介绍:
Commencing in 1969, the Journal of Economic Literature (JEL) serves as a vital resource for economists, offering a means to stay informed about the extensive literature in the field. Each JEL issue features commissioned, peer-reviewed survey and review articles, book reviews, an annotated bibliography categorizing new books by subject, and an annual index of dissertations from North American universities.